• PND57 TEMPORAL TRENDS AND GEOGRAPHIC DISCREPANCIES IN PUBLIC EXPENDITURES WITH MULTIPLE SCLEROSIS DRUG TREATMENT IN BRAZIL

    May 1, 2011, 00:00

  • PHP77 THE STATE OF HEALTH ECONOMICS AND PHARMACOECONOMICS RESEARCH IN RUSSIA- A SYSTEMATIC REVIEW

    May 1, 2011, 00:00

  • PCN132 MODELING THE LIFETIME EFFECTIVENESS OF DENOSUMAB AND ZOLEDRONIC ACID (ZA) IN THE PREVENTION OF SKELETAL RELATED EVENTS (SRE) IN PATIENTS WITH BONE METASTASES FROM SOLID TUMORS

    May 1, 2011, 00:00

  • PSS11 COST-EFFECTIVENESS ANALYSIS OF FORMULARY MANAGEMENT STRATEGIES FOR FIRST-LINE AGENTS USED IN OPEN-ANGLE GLAUCOMA AND OCULAR HYPERTENSION

    May 1, 2011, 00:00

  • PIH9 COSTS TO THE NATIONAL HEALTH INSURACE SCHEME OF THE FREE MATERNAL HEALTH SERVICE CHALLENGES AND IMPLICATIONS FOR SUSTAINABILITY IN GHANA

    May 1, 2011, 00:00

  • PCV71 EVALUATING MEDICATION ADHERENCE WITH CHRONIC CARDIOVASCULAR THERAPIES AMONG UNINSURED WORKING ADULTS- RESULTS FROM THE TEXAS DEMONSTRATION TO MAINTAIN INDEPENDENCE AND EMPLOYMENT (DMIE) STUDY

    May 1, 2011, 00:00

  • PMH40 COST-EFFECTIVENESS AND BUDGET IMPACT OF ADJUNCT QUETIAPINE FUMARATE EXTENDED-RELEASE IN PATIENTS WITH MAJOR DEPRESSIVE DISORDER WITH AN INADEQUATE RESPONSE TO PREVIOUS THERAPY

    May 1, 2011, 00:00

  • PHP32 ANALYSIS OF PHARMACISTS' INTERVENTIONS ON ELECTRONIC VERSUS TRADITIONAL PRESCRIPTIONS IN TWO COMMUNITY PHARMACIES

    May 1, 2011, 00:00

  • PMS41 PATIENT BURDEN OF GOUT- RESULTS FROM THE UNITED STATES NATIONAL HEALTH AND WELLNESS SURVEY (NHWS)

    May 1, 2011, 00:00

  • PMD35 SHORT TERM OUTCOMES ASSOCIATED WITH A CHANGE IN REIMBURSEMENT FOR DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE

    May 1, 2011, 00:00

  • DS1 INTEGRATING DATA SOURCES TO CONDUCT COMPREHENSIVE ONCOLOGY BASED OUTCOMES RESEARCH

    May 1, 2011, 00:00

  • PRM35 DEVELOPMENT OF A CONCEPT LIST TO ENSURE COMPARABLE CONTENT VALIDITY BETWEEN ORIGINAL PRO QUESTIONNAIRES AND THEIR TRANSLATIONS- A REVIEW OF 15 YEARS OF LINGUISTIC VALIDATIONS

    May 1, 2011, 00:00

  • PDB40 EXAMINING ADHERENCE WITH MEDICATIONS USED IN TREATING DIABETIC PERIPHERAL NEUROPATHIC PAIN AND THEIR ASSOCIATION WITH ORAL ANTIDIABETIC MEDICATION ADHERENCE

    May 1, 2011, 00:00

  • PCN24 FACTORS ASSOCIATED WITH LATE-STAGE PROSTATE CANCER SURVIVAL IN FLORIDA

    May 1, 2011, 00:00

  • PMS6 THE PREVALENCE OF BONE FRACTURES IN OSTEOPOROSIS PATIENTS USING PROTON PUMP INHIBITORS

    May 1, 2011, 00:00

  • PSS2 DIAGNOSED AND UNDIAGNOSED DRY EYE, SYMPTOM SEVERITY, AND ASSOCIATED FACTORS AMONG MEN AND WOMEN IN THE UNITED STATES

    May 1, 2011, 00:00

  • PIH20 ECONOMIC EVALUATION OF THE USE OF EXOGENOUS PULMONARY SURFACTANTS IN PRETERM NEWBORNS WITH RESPIRATORY DISTRESS SYNDROME IN MEXICAN POPULATION COVERED BY THE NEW GENERATION MEDICAL INSURANCE

    May 1, 2011, 00:00

  • PCV50 COST-EFFECTIVENESS ANALYSIS COMPARING DABIGATRAN AND ADJUSTED-DOSE WARFARIN FOR STROKE PREVENTION IN ATRIAL FIBRILLATION

    May 1, 2011, 00:00

  • PMS66 EARLY AND SUSTAINED REMISSION ASSOCIATED WITH NORMALIZED PHYSICAL FUNCTION AND HEALTH-RELATED QUALITY OF LIFE AND SIGNIFICANTLY IMPROVED PRODUCTIVITY IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS TREATED WITH GOLIMUMAB- TWO YEAR DATA FR ...

    May 1, 2011, 00:00

  • PIN7 EPIDEMIOLOGY OF HIV-RELATED NEUROPATHY – A SYSTEMATIC LITERATURE REVIEW

    May 1, 2011, 00:00

  • PCN23 IMPACT OF US FOOD AND DRUG ADMINISTRATION'S BLACK BOX WARNINGS ON ADVERSE EVENTS REPORTING RATES FOR MULTIPLE MYELOMA DRUGS

    May 1, 2011, 00:00

  • PRS34 PATIENT SELF-MANAGEMENT OF ASTHMA- A STUDY IN AN EMERGENCY ROOM OF A CHEST HOSPITAL IN DELHI, INDIA

    May 1, 2011, 00:00

  • PSU24 AGREEMENT BETWEEN PROMIS DEPRESSION, SLEEP DISTURBANCE, AND FATIGUE CAT MEASURES AND SF-36 SCORES IN A CLINICAL COHORT

    May 1, 2011, 00:00

  • PUK4 CUMULATIVE EXPOSURE TO NONSTEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS) AND THE PROGRESSION OF CHRONIC KIDNEY DISEASE (CKD)

    May 1, 2011, 00:00

  • PMS69 THE USE OF MIXED TREATMENT COMPARISONS IN NICE TECHNOLOGY APPRAISALS

    May 1, 2011, 00:00

  • PCV64 ADHERENCE TO MEDICATIONS WITH ONCE-A-DAY (QD) AND TWICE-A-DAY (BID) DOSING FORMULATIONS IN ACUTE CORONARY SYNDROME (ACS) PATIENTS

    May 1, 2011, 00:00

  • PSY68 DEFINITIONS OF ANTI-TNF DISCONTINUATION MAY IMPACT UNDERSTANDING OF REAL-WORLD UTILIZATION PATTERNS

    May 1, 2011, 00:00

  • PCV98 USE OF ELECTRONIC MEDICAL RECORDS TO ASSESS THE CLINICAL AND ECONOMIC IMPACT OF NON-MEDICAL SWITCHING BETWEEN DIFFERENT ANGIOTENSIN RECEPTOR BLOCKERS (ARBS)

    May 1, 2011, 00:00

  • PND43 THE PATIENTSLIKEME® EPILEPSY COMMUNITY- A UNIQUE INSIGHT INTO THE LIVES OF PATIENTS WITH EPILEPSY

    May 1, 2011, 00:00

  • PHP92 RESULTS OF A PHARMACY MANAGEMENT PROGRAM FOR IMPROVING MEDICATION ADHERENCE

    May 1, 2011, 00:00

  • PHP53 A RAPID EVALUATION UNIT INCREASES EMERGENCY DEPARTMENT VISITS

    May 1, 2011, 00:00

  • PCV91 BETA BLOCKERS AND DIURETICS USAGE IN CROATIA AND SLOVENIA DURING A NINE-YEAR PERIOD

    May 1, 2011, 00:00

  • PRM37 THE DISCRETE MODELLING OF INTERVENTIONS WITH CONTINUOUSLY VARYING COSTS AND EFFECTS- IMPLICATIONS FOR ICERS, CEACS AND EVPI

    May 1, 2011, 00:00

  • PMS46 IMPACT OF ETANERCEPT ON WORK AND ACTIVITY IMPAIRMENT IN EMPLOYED PATIENTS WITH MODERATE TO SEVERE RHEUMATOID ARTHRITIS

    May 1, 2011, 00:00

  • PHP100 PRICING AND REIMBURSEMENT OF ORPHAN DRUGS IN CANADA

    May 1, 2011, 00:00

  • PCN22 ASSESSMENT OF SAFETY PROFILE OF TRASTUZUMAB IN METASTATIC BREAST CANCER PATIENTS

    May 1, 2011, 00:00

  • PRS43 REGRESSION VERSUS PROPENSITY MATCHING AS OUTCOME ANALYSIS ADJUSTMENT METHODS- EXAMPLE USING COPD INITIAL THERAPIES

    May 1, 2011, 00:00

  • PND13 BURDEN OF ILLNESS IN THE UNITED STATES FOR PEDIATRIC EPILEPSY PATIENTS WITH PARTIAL ONSET SEIZURES RECEIVING ANTI-EPILEPTIC DRUGS

    May 1, 2011, 00:00

  • PCN14 UNMET NEED IN METASTATIC PROSTATE CANCER PATIENTS- RESULTS FROM A SYSTEMATIC REVIEW

    May 1, 2011, 00:00

  • PHP25 THE POTENTIAL VALUE OF THE 2014 MEDICAID EXPANSION

    May 1, 2011, 00:00

  • PIN15 ECONOMIC BURDEN OF SURGICAL SITE INFECTIONS IN HIP AND KNEE ARTHROPLASTY - A COST-OF-ILLNESS-STUDY FOR GERMANY

    May 1, 2011, 00:00

  • PMH26 MEDICATION ADHERENCE AND HEALTH CARE COSTS AMONG PATIENTS WITH MAJOR DEPRESSIVE DISORDER TREATED WITH DULOXETINE

    May 1, 2011, 00:00

  • PHP40 HEALTH CARE REFORMS UNDER ECONOMIC CRISIS- THE GREEK CASE

    May 1, 2011, 00:00

  • PCV54 EFFECTIVENESS OF DISEASE MANAGEMENT CARE IN THE CASE OF HEART FAILURE

    May 1, 2011, 00:00

  • PMS74 PILOT VALIDATION OF THE BRIEF PAIN INVENTORY ‘PAIN AT ITS WORST’ ITEM IN PATIENTS WITH RHEUMATOID ARTHRITIS

    May 1, 2011, 00:00

  • PIH42 A NET BENEFIT FRAMEWORK (NBF) ANALYSIS OF CHART DATA FOR HAEMOPHILIA INHIBITOR PATIENTS

    May 1, 2011, 00:00

  • PND10 BUDGET IMPACT ANALYSIS OF EVEROLIMUS FOR THE TREATMENT OF GROWING SUBEPENDYMAL GIANT CELL ASTROCYTOMA SECONDARY TO TUBEROUS SCLEROSIS COMPLEX

    May 1, 2011, 00:00

  • PUK21 PATIENT CHARACTERISTICS ASSOCIATED WITH INITIATION OF OVERACTIVE BLADDER (OAB) DISCUSSION WITH A PHYSICIAN

    May 1, 2011, 00:00

  • PHP98 A TREND ANALYSIS OF NEW MOLECULAR ENTITIES WITHDRAWN FOR SAFETY REASONS FROM 1980 TO 2009 IN THE UNITED STATES

    May 1, 2011, 00:00

  • PCN67 ERCC1 EXPRESSION TESTING IN STAGE I NON-SMALL CELL LUNG CANCER- POTENTIAL CLINICAL AND ECONOMIC OUTCOMES

    May 1, 2011, 00:00

  • PMH75 PSYCHIATRIC MORBIDITY AND BURNOUT AMONG HOSPITAL PHYSICIANS AND NURSES- ASSOCIATION WITH PERCEIVED JOB-RELATED FACTORS

    May 1, 2011, 00:00

  • PSS6 SAFETY PROFILE OF LATANOPROST VERSUS TIMOLOL IN PATIENTS WITH OPEN ANGLE GLAUCOMA OR OCULAR HYPERTENSION- POST 2000 SETTING

    May 1, 2011, 00:00

  • PND27 MEDICO-ECONOMIC EVALUATION OF LACOSAMIDE ADJUNCTIVE THERAPY IN THE TREATMENT OF PATIENTS WITH REFRACTORY EPILEPSY IN THE UNITED STATES

    May 1, 2011, 00:00

  • PND11 THE ECONOMIC BURDEN OF OSA IN EACH OF THE METABOLIC SYNDROME COMPONENTS LEVELS

    May 1, 2011, 00:00

  • PCV40 COST AND PRACTICE OF TREATMENT OF ACUTE ISCHEMIC STROKE IN REAL WORLD SETTINGS IN RUSSIA

    May 1, 2011, 00:00

  • PSY27 REAL-WORLD EVALUATION OF HEALTH CARE RESOURCE UTILIZATION AND COSTS IN PATIENTS WITH NEUROPATHIC PAIN ASSOCIATED WITH DIABETIC PERIPHERAL NEUROPATHY (PDPN) TREATED WITH PREGABALIN OR GABAPENTIN

    May 1, 2011, 00:00

  • PRS10 COST ANALYSIS OF VARENICLINE VERSUS NICOTINE REPLACEMENT THERAPY AND UNAIDED CESSATION IN NICARAGUA

    May 1, 2011, 00:00

  • PHP2 TRENDS IN AND PREDICTORS OF DISCOUNT GENERIC MEDICATION PROGRAM UTILIZATION

    May 1, 2011, 00:00

  • PSY34 CALCULATING PROMIS FATIGUE ITEM BANK IRT PARAMETER ESTIMATES SPECIFIC TO PATIENTS WITH FIBROMYALGIA

    May 1, 2011, 00:00

  • PCN54 INJECTION OF LONG-ACTING SOMATOSTATIN ANALOGS- A COST CONSEQUENCE ANALYSIS IN FRANCE, GERMANY, THE UNITED KINGDOM AND THE UNITED STATES

    May 1, 2011, 00:00

  • PHP19 TRENDS IN ON-LABEL AND OFF-LABEL PRESCRIBING OF MONTELUKAST IN A COMMERCIALLY INSURED POPULATION 1998-2008

    May 1, 2011, 00:00

  • PMS52 PREDICTORS OF BISPHOSPHONATE PRESCRIPTION IN PATIENTS WITH OSTEOPOROSIS

    May 1, 2011, 00:00

  • PCV47 COST-EFFECTIVENESS OF FONDAPARINUX AND ENOXAPARIN IN PATIENTS WITH NON ST-SEGMENT ELEVATION ACUTE CORONARY SYNDROME IN BRAZIL

    May 1, 2011, 00:00

  • PGI17 HCV TREATMENT CONTINUATION RATES IN GENOTYPE 1 PATIENTS IN A REAL-WORLD SETTING IN THE UNITED STATES

    May 1, 2011, 00:00

  • PSU3 LONG-TERM CLINICAL EFFECTIVENESS AND STABILITY OF LASIK AND SURFACE ABLATION IN KOREA- A SYSTEMATIC REVIEW APPROACH

    May 1, 2011, 00:00

  • PRS29 KNOWLEDGE, AWARENESS AND PERCEPTION OF TUBERCULOSES (TB) AMONG STUDENTS RESIDING IN UNIVERSITY HOSTELS

    May 1, 2011, 00:00

  • PMD29 PATIENT TIME AND INDIRECT COSTS ASSOCIATED WITH SENSOR-AUGMENTED INSULIN PUMP THERAPY IN TYPE 1 DIABETES

    May 1, 2011, 00:00

  • PND23 ECONOMIC EVALUATION OF DEXMEDETOMIDINE FOR SEDATION IN THE INTENSIVE CARE UNIT

    May 1, 2011, 00:00

  • PCN131 REPRESENTING UNCERTAINTY IN CALIBRATED CANCER TREATMENT MODELS- A PRACTICAL APPROACH

    May 1, 2011, 00:00

  • PSU21 THE REUSE OF SINGLE-USE SURGICAL DEVICES- EVALUATION OF THE ECONOMIC EVIDENCE

    May 1, 2011, 00:00

  • PIH14 PROJECTING THE POTENTIAL COST-EFFECTIVENESS OF UNIVERSAL ACCESS TO MODERN CONTRACEPTIVES IN UGANDA

    May 1, 2011, 00:00

  • PDB61 DECOMPOSING GENDER DIFFERENCES IN ANGIOTENSIN II CONVERTING ENZYME INHIBITORS AND ANGIOTENSIN RECEPTOR BLOCKERS AMONG VETERANS WITH DIABETES

    May 1, 2011, 00:00

  • PUK24 USE OF BIOMARKERS IN PROPENSITY SCORE MATCHING TO MITIGATE CHANNELING BIAS IN A RETROSPECTIVE COHORT OF ESRD PATIENTS

    May 1, 2011, 00:00

  • PIN1 VACCINE-ASSOCIATED GUILLAIN-BARRE SYNDROME- A PHARMACOVIGILANCE ANALYSIS OF DATA IN THE UNITED STATES' VACCINE ADVERSE EVENT REPORTING SYSTEM (1990-2009)

    May 1, 2011, 00:00

  • PHP82 THE IMPACT OF INTEGRATED MEDICAL CARE SERVICES FOR LOYAL PATIENTS IN A 2000-BED MEDICAL CENTER UNDER TAIWAN'S UNIVERSAL HEALTH INSURANCE PROGRAM

    May 1, 2011, 00:00

  • PCV5 PREVALENCE, INCIDENCE, AND OUTCOMES OF CRITICAL LIMB ISCHEMIA IN THE MEDICARE POPULATION IN THE UNITED STATES

    May 1, 2011, 00:00

  • PSS13 INCREMENTAL COST-UTILITY ANALYSIS OF DEXAMETHASONE INTRAVITREAL IMPLANT FOR THE TREATMENT OF MACULAR EDEMA FOLLOWING RETINAL VEIN OCCLUSION

    May 1, 2011, 00:00

  • PHP70 PREVENTABLE HOSPITALIZATIONS AND HEALTH INSURANCE COVERAGE IN HARRIS COUNTY, TEXAS

    May 1, 2011, 00:00

  • PCV109 BEYOND CASE FATALITY- A NEW METHOD TO ESTIMATE THE EFFECT OF INCREASING TREATMENT UPTAKE ON MORTALITY

    May 1, 2011, 00:00

  • PCN119 VALIDATION OF A NEW MEASURE OF PATIENT EMPOWERMENT IN ONCOLOGY- FIVE HEALTH EDUCATION IMPACT QUESTIONNAIRE (HEIQ) SCALES

    May 1, 2011, 00:00

  • PMD8 POSITRON EMISSION TOMOGRAPHY SCREENING FOR LUNG CANCER- A SYSTEMATIC REVIEW

    May 1, 2011, 00:00

  • PMH11 PERFORMANCE OF RISK ADJUSTMENT SCALES IN PREDICTING RISK OF HOSPITALIZATION AMONG DEMENTIA PATIENTS- A MEPS STUDY

    May 1, 2011, 00:00

  • PSY62 PERCEIVED BENEFITS AND DISADVANTAGES OF INTRAVENOUS (IV) BIOLOGIC THERAPY AMONG PATIENTS WITH IMMUNOLOGY CONDITIONS

    May 1, 2011, 00:00

  • PRM47 DEVELOPMENT OF LOCALLY ADAPTABLE VALUE ARGUMENTS- HOW CAN BUCKETING OF COUNTRIES AT GLOBAL LEVEL HELP MANUFACTURERS?

    May 1, 2011, 00:00

  • PMH79 PSYCHOTROPIC POLYPHARMACY IN CHILDREN AND ADOLESCENTS WITH ATTENTION – DEFICIT / HYPERACTIVITY DISORDER

    May 1, 2011, 00:00

  • PIH1 HEALTH-RELATED QUALITY OF LIFE (HRQOL) OF PATIENTS WITH CHRONIC CONDITIONS- EXCESS BURDEN OF COMORBID PHYSICAL AND MENTAL CHRONIC CONDITIONS

    May 1, 2011, 00:00

  • PIN38 RIGHT IMMUNIZATION DOSES RECEIVED BY PEDIATRIC YOUNGER THAN 2 YEARS

    May 1, 2011, 00:00

  • PND25 ECONOMIC TRENDS ASSOCIATED WITH NATALIZUMAB THERAPY IN A COMMERCIALY MANAGED MULTIPLE SCLEROSIS POPULATION

    May 1, 2011, 00:00

  • PHP104 CURRENT USES OF AND PERCEPTIONS ABOUT FDAMA SECTION 114

    May 1, 2011, 00:00

  • PRM44 OPTIMUM METHODS FOR PRO TRANSLATION AND LINGUISTIC VALIDATION METHODOLOGY- ONE BACK TRANSLATION OR TWO?

    May 1, 2011, 00:00

  • PMH18 IMPACT OF COGNITIVE IMPAIRMENT ON FUNCTIONING, MEDICAL RESOURCE UTILIZATION, ADHERENCE AND HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH SCHIZOPHRENIA

    May 1, 2011, 00:00

  • PRS23 NON-ADHERENCE IN ISONIAZID TREATED PATIENTS AS MEASURED BY THE TEMPTATION TO SKIP THERAPY (TEST) SCALE

    May 1, 2011, 00:00

  • PMH66 MULTIMORBIDITY AND DEPRESSION TREATMENT

    May 1, 2011, 00:00

  • PSS17 THE EFFECT OF ORAL CP-690,550 ON PRURITUS IN PATIENTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS

    May 1, 2011, 00:00

  • PHP64 THE RELATIONSHIP BETWEEN FINANCIAL IMPACT AND THE LIKELIHOOD OF DRUG REIMBURSEMENT IN THE AUSTRALIAN HEALTH CARE SYSTEM

    May 1, 2011, 00:00

  • PSY80 PRIORITIZATION AND WEIGHTING OF PATIENT-RELEVANT ENDPOINTS (PRES) AS PART OF THE IQWIGS EFFICIENCY FRONTIER METHOD IN GERMANY

    May 1, 2011, 00:00

  • PUK10 KIT73 STUDY- RELATIONSHIP BETWEEN COSTS OF CARE AND 12-MONTH GLOMERULAR FILTRATION RATES IN POST-KIDNEY TRANSPLANT PATIENTS IN THE BRAZILIAN PUBLIC HEALTH CARE SYSTEM (SUS)

    May 1, 2011, 00:00

  • PCV103 PHARMACIST INTERVENTIONS WITHIN A COMMUNITY PHYSICIAN BASED MEDICAL HOME PRACTICE- DIABETES CLINICAL OUTCOMES

    May 1, 2011, 00:00

  • PIH18 THE IMPACT OF LONG-TERM DISABILITY COSTS ARISING FROM IN-VITRO FERTILIZATION (IVF) TREATMENT- THE COST-EFFECTIVENESS ANALYSIS OF REDUCING MULTIPLE BIRTHS

    May 1, 2011, 00:00

  • PCN126 OVERVIEW OF PRIMARY ENDPOINTS, PROGRESSION-FREE SURVIVAL (PFS) AND OVERALL SURVIVAL (OS) FOR NON-SMALL CELL LUNG CANCER (NSCLC)- THEIR VALUE IN TREATMENT DECISIONS AND PATIENT CARE

    May 1, 2011, 00:00

  • PCN65 ECONOMIC EVALUATION OF THREE FORMULATIONS OF LEUPROLIDE ACETATE IN ANDROGEN DEPRIVATION THERAPY FOR ADVANCED PROSTATE CANCER IN PORTUGAL

    May 1, 2011, 00:00

  • PMS48 IMPACT OF ANTI-TNF ON HEALTH CARE UTILIZATION AND COSTS IN PATIENTS WITH RHEUMATOID ARTHRITIS IN ALBERTA, CANADA

    May 1, 2011, 00:00

  • PMD15 ECONOMIC EVALUATION OF SELF-MONITORING OF BLOOD GLUCOSE REGIMES PLUS CONVENTIONAL PHARMACOLOGIC TREATMENT FOR TYPE-2 DIABETIC PATIENTS IN MEXICO- ESTIMATION BY DISCRETE EVENT SIMULATION

    May 1, 2011, 00:00

  • PND16 CHARACTERIZING DIRECT COSTS ASSOCIATED WITH HEMOPHILIA A- A RESOURCE-BASED COST ANALYSIS

    May 1, 2011, 00:00

  • PIN20 A COST BENEFIT ANALYSIS OF ANTI-RETROVIRAL (ARVS) DRUGS IN THE TREATMENT OF HIV IN UGANDA

    May 1, 2011, 00:00

  • PMH42 ECONOMIC EVALUATION OF DESVENLAFAXINE IN THE ACUTE MANAGEMENT OF ASSOCIATED MAJOR DEPRESSIVE DISORDER IN MEDICALLY ILL INPATIENTS FROM A BRAZILIAN PUBLIC GENERAL HOSPITAL PERSPECTIVE

    May 1, 2011, 00:00

  • PMD17 ANALYSIS OF COST DRIVERS IN STRUCTURED SMBG IN POORLY CONTROLLED, NON-INSULIN TREATED TYPE-2 DIABETES- RESULTS FROM THE STEP STUDY

    May 1, 2011, 00:00

  • PRS18 THE COST-EFFECTIVENESS OF ROFLUMILAST IN THE MANAGEMENT OF SEVERE COPD IN THE UK SETTING

    May 1, 2011, 00:00

  • PRS7 USE OF INHALED TOBRAMYCIN IS ASSOCIATED WITH REDUCED MORTALITY IN PATIENTS WITH CYSTIC FIBROSIS

    May 1, 2011, 00:00

  • PSY71 HEALTH AND FUNCTIONAL STATUS FOR INDIVIDUALS WITH THROMBOCYTOPENIA IN THE UNITED STATES- EVIDENCE FROM NHANES

    May 1, 2011, 00:00

  • PSY24 COST-UTILITY ANALYSES OF DIFFERENT ERYTROPOIETINS IN ANEMIC PATIENTS ON DIALYSIS IN RUSSIA

    May 1, 2011, 00:00

  • PGI21 HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH MILD-TO-MODERATE ULCERATIVE COLITIS BEFORE AND AFTER 8 WEEKS' TREATMENT WITH MULTI-MATRIX MESALAMINE- COMPARISON WITH 2009 GENERAL POPULATION NORMS IN THE UNITED STATES

    May 1, 2011, 00:00

  • PIN28 ESTIMATED HEALTH AND ECONOMIC IMPACT OF QUADRIVALENT HPV TYPES 6, 11, 16, 18 VACCINE IN BRAZIL USING A TRANSMISSION DYNAMIC MODEL

    May 1, 2011, 00:00

  • PCN58 IS CYP2D6 GENETIC TEST IN COMBINATION WITH HORMONE THERAPY FOR ER+ HORMONE SENSITIVE WOMEN WITH EARLY BREAST CANCER COST-EFFECTIVE?

    May 1, 2011, 00:00

  • PMS65 RHEUMATOID ARTHRITIS PATIENT EXPERIENCE WITH SELF-INJECTION WITH SUBCUTANEOUS BIOLOGICS

    May 1, 2011, 00:00

  • PCN28 COST SAVINGS WITH FERRIC CARBOXYMALTOSE THROUGH ITS IMPACT ON ERYTHROPOÏESIS-STIMULATING AGENTS AND BLOOD TRANSFUSION IN CHEMOTHERAPY-INDUCED ANEMIA OF BREAST AND GASTROINTESTINAL CANCER- FRENCH HEALTH CARE PAYER PERSPECTIVE

    May 1, 2011, 00:00

  • PRS12 A NATIONAL SURVEY OF SOCIETAL COST OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE IN SOUTH KOREA

    May 1, 2011, 00:00

  • PUK6 LOW-MOLECULAR-WEIGHT HEPARIN IN CHRONIC HEMODIALYSIS PATIENTS- A SYSTEMATIC REVIEW AND META-ANALYSIS

    May 1, 2011, 00:00

  • PSS24 MEDICATION CHOICE AND ASSOCIATED HEALTH CARE OUTCOMES AND COSTS FOR PATIENTS WITH ACNE AND ACNE RELATED CONDITIONS IN THE UNITED STATES

    May 1, 2011, 00:00

  • PCN97 IMPACT OF GLOBAL HEALTH CARE REFORMS ON PRICING, ACCESS AND HEALTH ECONOMICS AND OUTCOMES STRATEGY

    May 1, 2011, 00:00

  • PDB11 COMPARISON OF MULTIVARIABLE-ADJUSTED LOGISTIC REGRESSION WITH PROPENSITY SCORE-MATCHED, PROPENSITY SCORE-STRATIFIED, AND PROPENSITY SCORE-ADJUSTED LOGISTIC REGRESSION MODELS

    May 1, 2011, 00:00

  • PSY25 RELATIONSHIP BETWEEN MONTHLY OUT-OF-POCKET HEALTHCARE COSTS AND WORK PRODUCTIVITY AMONG PATIENTS WITH INFLAMMATORY BOWEL DISEASE

    May 1, 2011, 00:00

  • EE2 VALIDATION OF THE UPDATED CHARLSON COMORBIDITY INDEX (CCI) TO PREDICT HEALTH CARE UTILIZATION FOR DIABETIC PATIENTS USING ADMINISTRATIVE DATA

    May 1, 2011, 00:00

  • PND35 CREATION OF A WEB-BASED MULTIPLE SCLEROSIS PATIENT-REPORTED OUTCOMES RESEARCH PROGRAM

    May 1, 2011, 00:00

  • PSY44 PAIN MANAGEMENT- IMPACT ON QUALITY OF LIFE

    May 1, 2011, 00:00

  • PND4 DIAGNOSIS OF SHIFT WORK DISORDER AND THE IMPACT OF EXCESSIVE SLEEPINESS- RESULTS FROM SHIFT WORKERS, PATIENTS WITH SHIFT WORK DISORDER, AND HEALTH CARE PROFESSIONALS PARTICIPATING IN AN INTERNET SURVEY

    May 1, 2011, 00:00

  • PMS23 COST-EFFECTIVENESS ANALYSIS OF ANALGESIC THERAPY FOR POSTOPERATIVE PAIN AFTER TOTAL HIP ARTHROPLASTY IN MEXICO

    May 1, 2011, 00:00

  • PRM6 DEVELOPMENT OF AN INCREMENTAL COST-EFFECTIVENESS RATIO WITH SOME EQUITY IMPLICATION

    May 1, 2011, 00:00

  • PSY66 BIOLOGIC EXPERIENCE AND DOSING OF GOLIMUMAB PATIENTS IN MANAGED CARE

    May 1, 2011, 00:00

  • PND31 HEADACHE DAY HEALTH STATES AND TRANSITION PROBABILITIES FOR PATIENTS WITH CHRONIC MIGRAINE WITH AND WITHOUT HEADACHE PROPHYLAXIS

    May 1, 2011, 00:00

  • PHP41 THE CHANGING LANDSCAPE OF ORPHAN DRUG PROVISION IN THE EU5 AND THE UNITED STATES

    May 1, 2011, 00:00

  • PCV8 EVALUATION OF A SAFETY INITIATIVE AND OUTCOMES FOR PATIENTS ON STATIN-FIBRATE COMBINATION THERAPIES IN THE VETERANS AFFAIRS POPULATION

    May 1, 2011, 00:00

  • PND48 MEASUREMENT CHARACTERISTICS OF THE SF-36 IN CHRONIC NEUROMUSCULAR DISORDER

    May 1, 2011, 00:00

  • PHP36 CATASTROPHIC INJURY-RELATED ENROLLMENT AND COSTS IN A STATE MEDICAID FEE-FOR-SERVICE PROGRAM

    May 1, 2011, 00:00

  • PSY67 REASONS FOR INITIATING INTRAVENOUS BIOLOGIC THERAPY AMONG PATIENTS WITH IMMUNOLOGY CONDITIONS- SUBSET ANALYSIS OF PRIOR SUBCUTANEOUS INJECTION (SQ) USERS AND IMPLICATIONS FOR SHARED DECISION MAKING

    May 1, 2011, 00:00

  • CE4 USING DYNAMIC TRANSMISSION MODELS TO ESTIMATE THE COST EFFECTIVENESS OF VACCINES- FOUR DIFFERENT METHODS AND THEIR RELEVANCE FOR DECISION MAKERS

    May 1, 2011, 00:00

  • PDB45 THE PATIENT REPORTED EXPERIENCE OF LIVING WITH DIABETIC PERIPHERAL NEUROPATHIC PAIN (DPNP)

    May 1, 2011, 00:00

  • PCN68 AN ECONOMIC EVALUATION OF DASATINIB FOR THE TREATMENT OF IMATINIB REISTANT PATIENTS WITH CHRONIC MYELOGENOUS LEUKAEMIA

    May 1, 2011, 00:00

  • PIH10 HEALTH CARE RESOURCE UTILIZATION AND COSTS IN FEMALES WITH NEWLY DIAGNOSED HEAVY MENSTRUAL BLEEDING- AN EMPLOYER'S PERSPECTIVE

    May 1, 2011, 00:00

  • PSY35 VALIDATION OF THE LUPUS IMPACT TRACKER

    May 1, 2011, 00:00

  • PRM46 R … YOU AWARE HOW USEFUL IT IS? THE VALUE OF CORRELATION COEFFICIENTS IN META-ANALYSIS

    May 1, 2011, 00:00

  • PIN40 DO PATIENTS AND PHYSICIANS HAVE SIMILAR PREFERENCES FOR HEALTH CARE DECISIONS INVOLVING UNCERTAIN OUTCOMES FOR CHRONIC HEPATITIS B IN GERMANY AND TURKEY?

    May 1, 2011, 00:00

  • PSY4 TRENDS IN HYPONATREMIA MANAGEMENT AND ASSOCIATED OUTCOMES IN HOSPITAL SETTINGS- INTERIM RESULTS FROM AN OBSERVATIONAL, PROSPECTIVE, MULTI-CENTER, GLOBAL REGISTRY IN HOSPITALIZED PATIENTS

    May 1, 2011, 00:00

  • PMS12 DIRECT AND INDIRECT COSTS ASSOCIATED WITH DUPUYTREN'S CONTRACTURE

    May 1, 2011, 00:00

  • PND33 UTILIZING A PAPER STANDARD GAMBLE INSTRUMENT TO ASSESS HEALTH UTILITY IN PATIENTS WITH HEMOPHILIA B

    May 1, 2011, 00:00

  • PRM5 A REVIEW AND CLASSIFICATION OF CONTINGENT VALUATION METHOD STUDIES IN SUB-SAHARA AFRICA

    May 1, 2011, 00:00

  • PSS15 DEVELOPMENT OF A MULTIATTRIBUTE INSTRUMENT FOR ESTIMATING UTILITIES (PREFERENCE WEIGHTS) IN PEOPLE WITH GLAUCOMA FROM THE NATIONAL EYE INSTITUTE VISUAL FUNCTIONING QUESTIONNAIRE (NEI-VFQ)

    May 1, 2011, 00:00

  • PSY78 ESTIMATING THE BMI-MORTALITY RELATION USING FRACTIONAL POLYNOMIALS

    May 1, 2011, 00:00

  • PHP96 REASONS FOR REJECTION OF PRO LABEL CLAIMS- AN ANALYSIS BASED ON A REVIEW OF PRO USE AMONG NEW MOLECULAR ENTITIES AND BIOLOGIC LICENSE APPLICATIONS 2006-2010

    May 1, 2011, 00:00

  • PGI8 COMPARING HEALTH-RISK BURDEN, LOST PRODUCTIVITY, AND TOTAL HEALTHCARE COSTS AMONG INDIVIDUALS WITH INFLAMMATORY BOWEL DISEASE AND FIVE MOST PREVALENT CHRONIC DISEASES

    May 1, 2011, 00:00

  • PMS32 ECONOMIC EVALUATION OF THE TREATMENT OF RHEUMATOID ARTHRITIS WITH ANTI-TNF BIOLOGICAL THERAPIES IN COLOMBIA

    May 1, 2011, 00:00

  • PGI6 THE ECONOMIC BURDEN OF ADVANCED LIVER DISEASE AMONG PATIENTS WITH HEPATITIS C VIRUS- A STATE MEDICAID PERSPECTIVE

    May 1, 2011, 00:00

  • PMD26 ECONOMIC EVALUATIONS FOR SCREENING AND TREATMENTS OF DIABETIC RETINOPATHY AND DIABETIC MACULAR EDEMA- A SYSTEMATIC REVIEW

    May 1, 2011, 00:00

  • PMS56 HEALTH CARE UTILIZATION AND PATIENT FINANCIAL BURDEN ANALYSIS OF PRE- VERSUS POST-DIAGNOSIS OF FIBROMYALGIA SYNDROME (FMS)

    May 1, 2011, 00:00

  • PMS15 COMPARING HEALTH-RISK BURDEN, LOST PRODUCTIVITY, AND TOTAL HEALTH CARE COSTS AMONG INDIVIDUALS WITH RHEUMATOID ARTHRITIS AND TOP FIVE CHRONIC DISEASES

    May 1, 2011, 00:00

  • PND12 LOWER DAILY AVERAGE CONSUMPTION AND GREATER PRESCRIPTION COST SAVINGS OF ARMODAFINIL COMPARED WITH MODAFINIL- A 12-MONTH RETROSPECTIVE DATABASE ANALYSIS

    May 1, 2011, 00:00

  • PMD37 A NATIONAL STUDY OF OUT-OF-POCKET EXPENDITURES FOR MAMMOGRAPHY SCREENING

    May 1, 2011, 00:00

  • PCV27 IS ANEMIA ASSOCIATED WITH HEART FAILURE? NHANES DATABASE (2005-2006) ANALYSIS

    May 1, 2011, 00:00

  • PMS33 COST EFFECTIVENESS OF ABATACEPT IN COMPARISON WITH OTHER BIOLOGIC THERAPIES FOR THE TREATMENT OF MODERATE TO SEVERE ACTIVE RHEUMATOID ARTHRITIS PATIENTS WHO HAVE FAILED TO METHOTREXATE BASED TREATMENT AT ESSALUD IN 2010

    May 1, 2011, 00:00

  • PHP5 INCENTIVE-BASED INTERVENTIONS – REWARDING PATIENTS FOR GOOD BEHAVIOUR

    May 1, 2011, 00:00

  • PHP109 AN OUTCOMES PROFILE REGISTRY FOR ESTABLISHING A BASELINE MATRIX IN COMPARATIVE EFFECTIVENESS STUDIES IN PREDICTIVE PHARMACOLOGY

    May 1, 2011, 00:00

  • PCN33 COST SAVINGS ASSOCIATED WITH TRANSFUSION INDEPENDENCE IN PATIENTS WITH MYELODYSPLASTIC SYNDROME WITH A 5Q- DELETION

    May 1, 2011, 00:00

  • DU2 PREVALENCE AND PREDICTORS OF POTENTIALLY SIGNIFICANT DRUG-DRUG INTERACTIONS IN THE ELDERLY

    May 1, 2011, 00:00

  • MC4 LONG TERM PERSISTENCE WITH ACEI/ARB THERAPY AFTER ACUTE MYOCARDIAL INFARCTION- AN ANALYSIS OF THE 2006-2007 MEDICARE 5% NATIONAL SAMPLE DATA

    May 1, 2011, 00:00

  • PSY75 PREVALENCE RATIOS AGAINST ODDS RATIOS AS EFFECT MEASURES IN A CROSS-SECTIONAL STUDY OF OBESITY AND ITS CHRONIC COMORBID CONDITIONS

    May 1, 2011, 00:00

  • PCV67 EXAMINING MEDICATION ADHERENCE AMONG TRICARE BENEFICIARIES RECEIVING STATIN THERAPY FOR SECONDARY PREVENTION OF CORONARY HEART DISEASE IN MILITARY TREATMENT FACILITIES IN THE UNITED STATES

    May 1, 2011, 00:00

  • PMH25 CLINICAL OUTCOMES AND ECONOMIC COSTS OF SECOND-GENERATION ANTIPSYCHOTICS IN PATIENTS WITH CHRONIC SCHIZOPHRENIA OR SCHIZOAFFECTIVE DISORDERS

    May 1, 2011, 00:00

  • PIH25 IMPACT OF PATIENT BEHAVIORS AND ATTITUDES ON TERIPARATIDE ADHERENCE IN A MEDICARE PART D POPULATION

    May 1, 2011, 00:00

  • PCV58 ASSOCIATION BETWEEN HEART FAILURE AND RESOURCE UTILIZATION IN ST-ELEVATION MYOCARDIAL INFARCTION PATIENTS TREATED WITH PERCUTANEOUS CORONARY INTERVENTION

    May 1, 2011, 00:00

  • PCN103 THE IMPACT OF INFUSION REACTIONS ASSOCIATED WITH MONOCLONAL ANTIBODIES IN METASTATIC COLORECTAL CANCER- A EUROPEAN PERSPECTIVE

    May 1, 2011, 00:00

  • PHP110 BIOSIMILARS LITERATURE REVIEW- THE CURRENT LANDSCAPE AND IMPLICATIONS OF RECENT HEALTH CARE LEGISLATION FOR THE UNITED STATES MARKET

    May 1, 2011, 00:00

  • PSU20 IS THERE INDICATION BIAS OF RETROSPECTIVE OBSERVATIONAL STUDY?

    May 1, 2011, 00:00

  • PGI24 DOES UTILITY OR CAPABILITY MATTER FOR IRRITABLE BOWEL SYNDROME? - A PRELIMINARY QUALITATIVE STUDY ON TAIWANESE PATIENTS

    May 1, 2011, 00:00

  • PCN77 USE OF SUBSTANCE ABUSE AMONG RESIDENTS OF KARACHI- REASONS AND COST OF USING SUBSTANCES

    May 1, 2011, 00:00

  • PND21 ESTIMATED COSTS OF FINGOLIMOD MONITORING FOR INDIVIDUALS WITH RELAPSING REMITTING MULTIPLE SCLEROSIS

    May 1, 2011, 00:00

  • PIN33 COST-UTILITY ANALYSIS OF RALTEGRAVIR IN HIV-INFECTED TREATMENT NAïVE PATIENTS IN SWEDEN

    May 1, 2011, 00:00

  • PND40 ASSESSMENT OF PERCEIVED SEVERITY OF DISEASE AND SYMPTOMS, QUALITY OF LIFE, WORK PRODUCTIVITY, AND HEALTH CARE RESOURCE USE IN INDIVIDUALS WITH MULTIPLE SCLEROSIS

    May 1, 2011, 00:00

  • PMH28 REAL-WORLD HEALTH CARE UTILIZATION AND COSTS IN NEWLY DIAGNOSED DEPRESSION PATIENTS BETWEEN 2006 AND 2008

    May 1, 2011, 00:00

  • PHP16 ANALYZING THE EUROPEAN EXTERNAL REFERENCE PRICING SYSTEM USING SPECTRAL GRAPH THEORY

    May 1, 2011, 00:00

  • PSS3 PERSISTENCE WITH STATINS AND THE RISK OF AGE RELATED MACULAR DEGENERATION IN A LARGE HEALTH ORGANIZATION IN ISRAEL

    May 1, 2011, 00:00

  • PDB35 UTILIZATION OF PHYSICIAN, NURSING AND DIETICIAN SERVICES BY TYPE 2 DIABETIC PATIENTS ATTENDING PRIMARY CARE CLINICS IN SINGAPORE

    May 1, 2011, 00:00

  • PRM29 METHODOLOGICAL DIFFERENCES IN EQ-5D SCORING SYSTEMS- A SYSTEMATIC REVIEW AND ANALYSIS

    May 1, 2011, 00:00

  • PSY69 MODELING THE IMPACT OF REFILL OR ADMINISTRATION GAPS ON PATIENT DRUG LEVELS OF THE TNF-ALPHA INHIBITORS ETANERCEPT AND INFLIXIMAB

    May 1, 2011, 00:00

  • PMS42 CONTENT VALIDITY AND HEALTH CARE SYSTEMS- A CASE-STUDY

    May 1, 2011, 00:00

  • PDB3 LONG-TERM ANTIPROTEINURIC EFFECT OF ALISKIREN IN DIABETIC PATIENTS WITH PERSISTENT ALBUMINURIA DESPITE CHRONIC ACEI OR ARB TREATMENT

    May 1, 2011, 00:00

  • PSY38 PATIENT-REPORTED OUTCOMES IN SUBJECTS WITH PAINFUL DIABETIC PERIPHERAL NEUROPATHY- PAIN DESCRIPTION AND QUALITY OF LIFE

    May 1, 2011, 00:00

  • PIN32 PHARMACOECONOMIC ANALYSIS OF MARAVIROC IN TREATMENT-EXPERIENCED HIV PATIENTS IN BRAZIL

    May 1, 2011, 00:00

  • PRS22 COPD MAINTENANCE MEDICATION ADHERENCE- INFLUENCE ON HOSPITALIZATION AND SPENDING IN A MEDICARE POPULATION

    May 1, 2011, 00:00

  • PDB54 USE OF ELECTRONIC MEDICAL RECORDS FOR CLINICAL RESEARCH IN THE MANAGEMENT OF TYPE-2 DIABETES

    May 1, 2011, 00:00

  • PMH20 PSYCHOTROPIC MEDICATION USE AMONG CHILDREN WITH AUTISM SPECTRUM DISORDER- A COMPARISON BETWEEN MEDICAID AND COMMERCIAL INSURANCE

    May 1, 2011, 00:00

  • PCV80 MEDICATION THERAPY MANAGEMENT IMPROVES HEALTH CARE UTILIZATION AND COSTS FOR EMPLOYERS

    May 1, 2011, 00:00

  • PIH37 DUAL VETERAN HEALTH ADMINISTRATION AND MEDICARE USE AND AMBULATORY CARE SENSITIVE HOSPITALIZATIONS

    May 1, 2011, 00:00

  • PHP66 DEMONSTRATING “DISEASE MODIFYING THERAPIES”? AN HTA PERSPECTIVE

    May 1, 2011, 00:00

  • PCV97 IS CARDIOVASCULAR MEDICATION USAGE A MARKER FOR CARDIOVASCULAR RISK? POTENTIAL IMPLICATION FOR SMART-EDIT FORMULARY MANAGEMENT STRATEGIES

    May 1, 2011, 00:00

  • PMS19 FRACTURE-RELATED TREATMENT COSTS ATTRIBUTABLE TO PROTON PUMP INHIBITOR USE IN OSTEOPOROSIS PATIENTS

    May 1, 2011, 00:00

  • PND24 QUALITY OF LIFE USING TREATMENTS FOR PARKINSON'S DISEASE- AN ECONOMIC COMPARISON BETWEEN ROPINIROLE AND LEVODOPA/CARBIDOPA

    May 1, 2011, 00:00

  • PCN53 RISK OF PERSONAL BANKRUPTCY FOLLOWING A CANCER DIAGOSIS

    May 1, 2011, 00:00

  • PMH12 THE PROFILE OF IMPAIRMENTS TO ATTENTION AND EPISODIC RECOGNITION MEMORY IN MILD COGNITIVE IMPAIRMENT AND ALZHEIMER'S DISEASE

    May 1, 2011, 00:00

  • PND63 LITTLE OR NO TREATMENT EFFECT? APPLICATION OF GROWTH MIXTURE MODELS TO EXPLORE UNKNOWN SUBGROUPS OF DIFFERENTIAL RESPONDERS TO TREATMENT

    May 1, 2011, 00:00

  • PMS58 BURDEN OF RHEUMATOID ARTHRITIS DISEASE FLARES

    May 1, 2011, 00:00

  • PHP94 THE ROLE OF HEALTH-RELATED QUALITY OF LIFE DATA IN THE DRUG APPROVAL PROCESSES IN THE UNITED STATES AND EUROPE- A REVIEW OF GUIDANCE DOCUMENTS AND AUTHORIZATIONS OF MEDICINAL PRODUCTS FROM 2006 TO 2010

    May 1, 2011, 00:00

  • PSY46 DISEASE SYMPTOMS, TREATMENT SATISFACTION, AND COPING STRATEGIES IN PATIENTS WITH LUPUS

    May 1, 2011, 00:00

  • PCN55 RACIAL VARIATION IN THE COST-EFFECTIVENESS OF CHEMOTHERAPY FOR PROSTATE CANCER

    May 1, 2011, 00:00

  • PSS4 SYSTEMATIC REVIEW OF THE EPIDEMIOLOGIC LITERATURE ON ATOPIC DERMATITIS IN CHILDREN

    May 1, 2011, 00:00

  • PCN37 ESTIMATING COST OF TREATMENT IN ELDERLY PATIENTS WITH COLORECTAL CANCER USING MEDICARE DATA

    May 1, 2011, 00:00

  • PCV57 HEALTH CARE RESOURCE UTILIZATION AMONG T2DM PATIENTS WITH PRE-EXISTING MACROVASCULAR CONDITIONS- A MATCHED COHORT STUDY

    May 1, 2011, 00:00

  • PCN104 HOSPITAL COSTS OF ADVERSE EVENTS IN PATIENTS RECEIVING TREATMENT FOR METASTATIC COLORECTAL CANCER

    May 1, 2011, 00:00

  • PIH36 DRUG PRESCRIBING BEHAVIOR FOR THE TREATMENT OF HEAVY MENSTRUAL BLEEDING

    May 1, 2011, 00:00

  • PCV108 CARDIOVERSION TREATMENT PATTERNS AND OUTCOMES AMONG ACUTE ATRIAL FIBRILLATION PATIENTS IN 5 EUROPEAN COUNTRIES

    May 1, 2011, 00:00

  • PSY63 LONGITUDINAL ANALYSIS OF INFLIXIMAB DOSING AND INFUSION INTERVALS ACROSS 30 INFUSIONS

    May 1, 2011, 00:00

  • PCN85 CANCER PATIENTS' PERCEPTION TOWARDS THE USE OF TRADITIONAL CM) FOR CANCER TREATMENT- A QUALITATIVE STUDY

    May 1, 2011, 00:00

  • PIH23 A SYSTEMATIC LITERATURE REVIEW OF BEHAVIORAL RISK FACTORS ASSOCIATED WITH INITIAL MEDICATION ADHERENCE

    May 1, 2011, 00:00

  • PCV89 COMPARISON OF DOSING PATTERNS AMONG PATIENTS INITIATING STATIN THERAPY IN A MANAGED CARE POPULATION

    May 1, 2011, 00:00

  • PCV51 THE VALUE OF ATORVASTATIN OVER THE PRODUCT LIFE CYCLE

    May 1, 2011, 00:00

  • PDB51 IMPROVING HEALTH INSURANCE AND PREVENTIVE EFFORT AMONG DIABETIC PATIENTS- THE COLOMBIAN EXPERIENCE

    May 1, 2011, 00:00

  • PSS22 SYSTEMATIC REVIEW OF THE QUALITY OF LIFE LITERATURE IN CHILDREN WITH ATOPIC DERMATITIS

    May 1, 2011, 00:00

  • PCV79 IMPACT OF DISEASE MANAGEMENT PROGRAM “DE TODO CORAZON” OF MUTUAL SER HMO TO CONTROL CARDIOVASCULAR RISK, COHORT 2004-2009, COLOMBIA

    May 1, 2011, 00:00

  • PUK8 KIT73 STUDY- DOES TYPE OF DONOR INFLUENCE LONG-TERM COSTS OF CARE? RESULTS FROM POST-KIDNEY TRANSPLANT PATIENTS IN THE BRAZILIAN PUBLIC HEALTH CARE SYSTEM (SUS)

    May 1, 2011, 00:00

  • PIN29 A COST-EFFECTIVENESS ANALYSIS ON THE USE OF DAPTOMYCIN FOR THE TREATMENT OF SKIN AND SOFT TISSUE INFECTIONS WITH FAILURE TO VANCOMYCIN THERAPY IN MEXICO

    May 1, 2011, 00:00

  • PCN6 BREAST, PROSTATE AND COLORECTAL CANCER SCREENING BEHAVIOR AND INCIDENCE OF LATE STAGE CANCER DIAGNOSIS IN ELDERLY WEST VIRGINIANS

    May 1, 2011, 00:00

  • PCV28 CARDIOVASCULAR RISK FACTORS AMONG CHINESE AND WHITE ADULTS IN THE UNITED STATES

    May 1, 2011, 00:00

  • PMH61 NATIONAL ESTIMATES AND CHARACTERISTICS OF AMBULATORY CARE VISITS FOR DEMENTIA CARE IN THE UNITED STATES, 1998–2007

    May 1, 2011, 00:00

  • PCN113 LEARNING THE LESSONS OF ONCOLOGY HTA REVIEWS IN AUSTRALIA THE UNITED KINGDOM – A CASE STUDY OF FIVE DRUGS

    May 1, 2011, 00:00

  • DS3 AVAILABILITY OF LABORATORY RESULTS DATA IN A CLAIMS DATABASE IN THE UNITED STATES

    May 1, 2011, 00:00

  • PSS25 MEDICATION ADHERENCE TO TOPICAL MEDICATIONS AND HEALTHCARE EXPENDITURES IN MEDICAID-ENROLLED CHILD WITH ATOPIC DERMATITIS

    May 1, 2011, 00:00

  • PMH8 EFFECT OF VARIOUS ANTIDEPRESSANT GROUPS ON BONE MINERAL DENSITY (BMD)

    May 1, 2011, 00:00

  • QA4 IS THE AIM OF THE HEALTH CARE SYSTEM TO MAXIMISE QALYS? AN INVESTIGATION OF ‘WHAT ELSE MATTERS’ IN THE NHS

    May 1, 2011, 00:00

  • PCN40 HEALTH CARE UTILIZATION AND COSTS OF RESECTED SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK (SCCHN) IN AN INCIDENT COHORT OF PATIENTS IN THE UNITED KINGDOM

    May 1, 2011, 00:00

  • PMH36 FACTORS ASSOCIATED WITH HEALTHCARE COSTS IN A POPULATION OF COMMERCIALLY INSURED CHILDREN AND ADOLESCENTS WITH ATTENTION DEFICIT/HYPERACTIVITY DISORDER AND PSYCHIATRIC COMORBIDITIES

    May 1, 2011, 00:00

  • PGI3 THE LIKELIHOOD OF HAVING FUNCTIONAL DYSPEPSIA BASED ON OTHER COMORBID CONDITIONS

    May 1, 2011, 00:00

  • PSY30 A REAL-WORLD EVALUATION OF ADHERENCE AND PERSISTENCE OF WEIGHT-LOSS PHARMACOTHERAPY IN THE UNITED STATES- 2007-2010

    May 1, 2011, 00:00

  • PMD40 METHODOLOGICAL CONSIDERATIONS IN MODELING THE ECONOMIC VALUE OF DIAGNOSTIC ACCURACY

    May 1, 2011, 00:00

  • PCV96 TREND IN THE UTILIZATION OF PHARMACOLOGICAL AND NON-PHARMACOLOGICAL TREATMENT STRATEGIES IN THE MANAGEMENT OF NEWLY DIAGNOSED ATRIAL FIBRILLATION PATIENTS IN THE UNITED STATES

    May 1, 2011, 00:00

  • PMS9 COST CONSEQUENCE OF COLCHICINE APPROVAL IN THE MEDICAID PROGRAMS IN THE UNITED STATES

    May 1, 2011, 00:00

  • PCN106 RESEARCH ON THE FACTORS AFFECTING THE ADOPTION OF HIGH VALUE MEDICAL CONSUMES IN LESS DEVELOPED AREAS OF CHINA

    May 1, 2011, 00:00

  • PDB22 INSULIN GLARGINE PLUS OHAS VERSUS BIPHASIC INSULIN IN TYPE-2 DIABETES – A COST COMPARISON

    May 1, 2011, 00:00

  • MC2 ASSESSING PREDICTORS OF MEDICATION ADHERENCE IN UNCONDITIONAL QUANTILE REGRESSION FRAMEWORK

    May 1, 2011, 00:00

  • PDB67 IT PROCESSES IN CLINICAL PRACTICES FOR DIABETES PATIENTS TYPE II

    May 1, 2011, 00:00

  • PGI2 PREDICTORS OF PROTON PUMP INHIBITOR (PPI) DOSING REGIMEN AMONG PATIENTS WITH GASTROESOPHAGEAL REFLUX DISEASE (GERD)

    May 1, 2011, 00:00

  • PUK12 COST-EFFECTIVENESS OF TOLTERODINE AS TREATMENT FOR OVERACTIVE BLADDER (OAB) IN ADULT MEXICAN PATIENTS

    May 1, 2011, 00:00

  • PCN101 HEALTH CARE RESOURCE UTILIZATION AND ECONOMIC BURDEN OF METASTATIC AND RECURRENT LOCALLY-ADVANCED HEAD AND NECK CANCER PATIENTS

    May 1, 2011, 00:00

  • PRM38 THE EXTENSION OF THE COST-EFFECTIVENESS ACCEPTABILITY CURVE- HOW TO MAKE IT MORE INFORMATIVE?

    May 1, 2011, 00:00

  • PHP85 APPLYING FUZZY MULTIPLE CRITERIA DECISION MAKING TO ESTABLISH A NEW HEALTH TECHNOLOGY ASSESSMENT SYSTEM WITH COVERAGE IMPLICATIONS IN TAIWAN NATIONAL HEALTH INSURANCE

    May 1, 2011, 00:00

  • PSU8 PATTERNS OF ACUTE CLOPIDOGREL USE AND INPATIENT COSTS IN ACUTE CORONARY SYNDROME PATIENTS UNDERGOING CORONARY ARTERY BYPASS GRAFTING

    May 1, 2011, 00:00

  • MD4 EVALUATION OF AN INTERVENTION TO REDUCE POLY-PHARMACY IN MEDICARE PART D

    May 1, 2011, 00:00

  • PCN78 THE DEVELOPMENT OF A VALUE BASED PRICING INDEX FOR NEW DRUGS IN METASTATIC COLORECTAL CANCER

    May 1, 2011, 00:00

  • PSU12 IMMUNOSUPPRESSANT THERAPY ADHERENCE AND REJECTION OUTCOMES IN LIVER AND KIDNEY TRANSPLANT PATIENTS

    May 1, 2011, 00:00

  • PSU5 LONG-TERM CLINICAL SAFETY OF LASIK AND SURFACE ABLATION IN SOUTH KOREA THROUGH LINKAGE OF RETROSPECTIVE COHORT AND NATIONWIDE CLAIMS DATABASE

    May 1, 2011, 00:00

  • PRS46 MEASUREMENT COMPARABILITY BETWEEN PAPER AND ALTERNATE VERSIONS- RECOMMENDED ASSESSMENT STEPS USING THE LUNG FUNCTION QUESTIONNAIRE AS AN EXAMPLE

    May 1, 2011, 00:00

  • PGI16 RESOURCE UTILIZATION AND HEALTH CARE COSTS ASSOCIATED WITH DIVERTICULAR DISEASE- RESULTS FROM A RETROSPECTIVE CLAIMS DATABASE ANALYSIS IN THE UNITED STATES

    May 1, 2011, 00:00

  • PMD21 IS CYBERKNIFE A COST-EFFECTIVE OPTION FOR TREATING PROSTATE CANCER?

    May 1, 2011, 00:00

  • PDB6 LONG-TERM EFFECTIVENESS OF MANAGING DIABETES WITH THE CHRONIC CARE MODEL- SIMULATIONS PERFORMED USING ARCHES

    May 1, 2011, 00:00

  • PRM39 LITERATURE REVIEW OF RANDOMIZED, CONTROLLED STUDIES OF THE IMPACT OF PHARMACISTS' INTERVENTIONS TO IMPROVE PATIENT OUTCOMES

    May 1, 2011, 00:00

  • PCV85 TREATMENT FOR DEPRESSION IN WOMEN WITH HYPERTENSION

    May 1, 2011, 00:00

  • CN1 MONOTHERAPY OF ANDROGEN DEPRIVATION THERAPY VERSUS RADICAL PROSTATECTOMY AMONG VETERANS WITH LOCALIZED PROSTATE CANCER- A COMPARATIVE EFFECTIVENESS ANALYSIS OF RETROSPECTIVE COHORTS

    May 1, 2011, 00:00

  • PCN70 USING PHARMACOECONOMIC MODELING TO DETERMINE A VALUE-BASED PRICE OF NEW CANCER DRUGS IN MALAYSIA

    May 1, 2011, 00:00

  • PND5 ASSESSMENT OF PARKINSON'S DISEAES PROGRESSION RATES BY STAGE OF DISEASE

    May 1, 2011, 00:00

  • PCV59 PERSISTENCE AND COMPLIANCE IN HYPERTENSIVE PATIENTS TREATED WITH FIXED OR UNFIXED COMBINATIONS OF ANGIOTENSIN RECEPTOR BLOCKERS, AMPLODIPINE AND HYDROCHLOROTHIAZIDE

    May 1, 2011, 00:00

  • PCV29 IMPROVING BLEEDING RISK ASSESSMENT FOR ANTICOAGULANT USE IN ATRIAL FIBRILLATION

    May 1, 2011, 00:00

  • PHP31 REVIEW OF HIGHLY SPECIALIZED MEDICAL SERVICES IN KAZKAHSTAN WITHIN AN INTRODUCTIN OF UNIFIED NATIONAL HEALTH SYSTEM

    May 1, 2011, 00:00

  • PSS16 DEVELOPMENT OF A DISEASE SPECIFIC VERSION OF THE EQ-5D FOR USE IN PSORIASIS

    May 1, 2011, 00:00

  • PMD16 COMPARISON OF COST AND CLINICAL OUTCOMES OF OPEN VERSUS LAPAROSCOPIC THORACIC PROCEDURES IN THE UNITED STATES

    May 1, 2011, 00:00

  • PCV102 COMPLICATIONS ARISING DURING HOSPITALIZATION FOR HEMORRHAGIC OR ISCHEMIC STROKE- EVIDENCE FROM A LARGE ADMINISTRATIVE DATABASE

    May 1, 2011, 00:00

  • PCV1 DOES ROUTE OF ADMINISTRATION FOR ESTROGEN HORMONE THERAPY IMPACT RISK OF VENOUS THROMBOEMBOLISM- ESTRADIOL TRANSDERMAL SYSTEM VERSUS ORAL ESTROGEN-ONLY HORMONE THERAPY

    May 1, 2011, 00:00

  • PHP84 AHRQ VERSUS NICE- DO THE CONCLUSIONS IN CER REPORTS CORRESPOND CLOSELY TO THE COMPARATIVE EFFECTIVENESS ASSESSMENTS MADE IN HTA REPORTS?

    May 1, 2011, 00:00

  • PDB76 DESIGNING A SERVICE FRAMEWORK FOR ELECTRONIC PERSONAL HEALTH RECORDS- A PATIENT-CENTRED APPROACH

    May 1, 2011, 00:00

  • PCV56 COST-MINIMIZATION ANALYSIS OF LANDIOLOL FOR CT SCANNING FOR CVD SUSPICIOUS PATIENTS IN JAPAN

    May 1, 2011, 00:00

  • PMH27 IDENTIFICATION AND COST OF TREATMENT-RESISTANT DEPRESSION USING A CLAIMS SIGNATURE

    May 1, 2011, 00:00

  • PIH34 IMPLEMENTATION OF A STATE MEDICAID PRESCRIPTION CAP POLICY- IS THERE AN IMPACT ON BENEFICIARIES' MEDICAL SERVICES UTILIZATION AND COSTS?

    May 1, 2011, 00:00

  • PCV25 MANAGEMENT OF ACUTE ISCHEMIC STROKE AND ITS LONG TERM EVOLUTION IN THE UNITED STATES AND CANADA

    May 1, 2011, 00:00

  • PMH33 THE EFFECTIVENESS OF BUPRENORPHINE-MEDICATION ASSISTED TREATMENT AMONG AETNA'S OPIOID DEPENDENT MEMBERS- AN ANALYSIS OF HEALTH CARE COSTS AND SERVICE UTILIZATION

    May 1, 2011, 00:00

  • PCN15 CORRELATES FOR HUMAN PAPILLOMA VIRUS VACCINATION UPTAKE IN A LARGE HEALTH ORGANIZATION IN ISRAEL

    May 1, 2011, 00:00

  • PMH21 DIFFERENCES IN DAILY AVERAGE CONSUMPTION AND DAILY COSTS OF DESVENLAFAXINE, VENLAFAXINE XR, DULOXETINE, AND ESCITALOPRAM AMONG COMMERCIALLY INSURED PATIENTS

    May 1, 2011, 00:00

  • PSS28 EFFECT OF DIFFERENT RECALL PERIODS ON DRY EYE SYMPTOM RATINGS

    May 1, 2011, 00:00

  • PSU15 DEVELOPMENT OF THE BARIATRIC AND OBESITY SPECIFIC SURVEY (BOSS)

    May 1, 2011, 00:00

  • PHP38 UTILIZATION, PRICE AND SPENDING OF ANTI-TUMOR NECROSIS FACTOR BIOLOGICS IN THE UNITED STATES MEDICAID PROGRAM

    May 1, 2011, 00:00

  • PCV38 POTENTIAL ECONOMIC IMPACT OF DYSPNEA ASSOCIATED WITH TICAGRELOR USE

    May 1, 2011, 00:00

  • PMH29 ESTIMATION OF DIRECT COSTS OF TREATING SCHIZOPHRENIA FOR COMMUNITY-DWELLING UNITED STATES RESIDENTS

    May 1, 2011, 00:00

  • PDB32 ECONOMIC EVALUATION OF RANIBIZUMAB FOR THE TREATMENT OF DIABETIC MACULAR EDEMA IN CANADA

    May 1, 2011, 00:00

  • PRM22 STAGES OF NON-PERSISTENCE- A NOVEL WAY OF FRAMING LONGITUDINAL PERSISTENCE TO CHRONIC MEDICATIONS

    May 1, 2011, 00:00

  • PHP7 DEVELOPING PUBLIC HEALTH GUIDANCE - WHAT ARE THE DATA GAPS? REVIEW OF THE GAPS IN THE EVIDENCE IDENTIFIED BY NICE IN THE UNITED KINGDOM

    May 1, 2011, 00:00

  • PIN39 IMMUNIZATION BARRIERS AND SUGGESTED SOLUTIONS IN IRAQ

    May 1, 2011, 00:00

  • PCN52 WILLINGNESS TO PAY AND COST BENEFIT ANALYSIS OF DELIVERY METHODS FOR DECISION SUPPORT FOR RURAL CANCER PATIENTS

    May 1, 2011, 00:00

  • PCV20 PERSISTENCE WITH STATINS AND PRIMARY PREVENTION OF CARDIOVASCULAR EVENTS- A POPULATION-BASED COHORT STUDY

    May 1, 2011, 00:00

  • PCN138 A REVIEW OF EXPANDED ACCESS PROGRAMS (EAP) AND THEIR CONSIDERATION BY HEALTH PLAN DECISION-MAKERS IN THE UNITED STATES

    May 1, 2011, 00:00

  • PHP99 WILL BIOPHARMACEUTICAL INNOVATION STILL BE A PICTURE OF HEALTH AFTER IMPLEMENTATION OF HEALTH CARE REFORM?

    May 1, 2011, 00:00

  • PSS1 STEVENS-JOHNSON AND RED MAN SYNDROME- A CASE REPORT ON ADVERSE DRUG REACTIONS OF SIMULTANEOUS USE OF PHENYTOIN AND VANCOMYCIN

    May 1, 2011, 00:00

  • PDB72 TWO-WAY INTERACTION EFFECT ANALYSIS OF DIABETES COMPLICATIONS ON HEALTH COSTS AND HEALTH OUTCOMES IN MEDICARE INPATIENTS

    May 1, 2011, 00:00

  • PND36 INTERNAL LOCUS OF CONTROL AND TREATMENT SATISFACTION WITH NATALIZUMAB

    May 1, 2011, 00:00

  • MD3 EVALUATING THE WILLINGNESS-TO-PAY OF MEDICARE BENEFICIARIES FOR PART D PLAN ASSISTANCE

    May 1, 2011, 00:00

  • PRS16 COST-EFFECTIVENESS OF VARENICLINE VERSUS EXISTING SMOKING CESSATION STRATEGIES IN CENTRAL AMERICA AND THE CARIBBEAN USING THE BENESCO MODEL

    May 1, 2011, 00:00

  • PRM34 EVALUATING THE SCREENING ABILITY OF PATIENT-REPORTED OUTCOME INSTRUMENTS

    May 1, 2011, 00:00

  • PND9 FACTORS AFFECTING FUNCTIONAL DEPENDENCE IN ALZHEIMER PATIENTS RESIDING IN NURSING HOMES IN THE UNITED STATES - USING NATIONAL NURSING HOME SURVEY (NNHS-2004)

    May 1, 2011, 00:00

  • PDB55 CLINICAL AND ECONOMIC EVALUATION OF A DIABETES MEDICATION MANAGEMENT PROGRAM- 2 YEAR PROGRAM UPDATE

    May 1, 2011, 00:00

  • PCV36 EVALUATION OF THE HOSPITAL RESOURCE UTILIZATION ASSOCIATED WITH TOLVAPTAN USAGE AMONG HEART FAILURE PATIENTS WITH HYPONATREMIA FROM THE EVEREST TRIAL

    May 1, 2011, 00:00

  • PMH85 A SCHIZOPHRENIA OR BIPOLAR TYPE I DISORDER REGISTRY- LESSONS LEARNED FROM CONDUCTING A REGISTRY STUDY WITH SAFETY NET PROVIDERS

    May 1, 2011, 00:00

  • PND58 INPATIENT HEALTH RESOURCE UTILIZATION AMONG MULTIPLE SCLEROSIS PATIENTS IN THE BRAZILIAN PUBLIC HEALTH CARE SYSTEM

    May 1, 2011, 00:00

  • PMH72 ANTIDEPRESSANT PERSISTENCE AND ASSOCIATED HEALTH CARE EXPENDITURES IN CHILDREN WITH DEPRESSION

    May 1, 2011, 00:00

  • PCN25 BUDGET-IMPACT OF ERIBULIN FOR THIRD-LINE TREATMENT OF METASTATIC BREAST CANCER IN A UNITED STATES MANAGED CARE SETTING

    May 1, 2011, 00:00

  • PHP23 THE IMPACT OF MEDICARE PART D ON PRESCRIPTION VOLUME AND OUT-OF-POCKET COSTS OF MEDICALLY NECESSARY DRUGS

    May 1, 2011, 00:00

  • PDB57 IMPACT OF A PHARMACIST-BASED DIABETES MANAGEMENT PROGRAM ON ADHERENCE TO MEDICATION FOR DIABETIC PATIENTS

    May 1, 2011, 00:00

  • PCV3 RISK OF HOSPITALIZATIONS FOR VENOUS THROMBOEMBOLISM IN ATYPICAL VERSUS TYPICAL ANTIPSYCHOTIC USERS IN A NATIONAL SAMPLE OF MEDICARE BENEFICIARIES- A CLAIMS DATA ANALYSIS

    May 1, 2011, 00:00

  • PHP57 PATTERNS OF INSURANCE COVERAGE IN THE UNITED STATES- ANALYSIS OF THE 2004-2007 MEDICAL EXPENDITURE PANEL SURVEYS (MEPS)

    May 1, 2011, 00:00

  • PCN9 VALUE OF RESEARCH ANALYSES IN RESEARCH PRIORITIZATION OF CANCER GENOMIC APPLICATIONS

    May 1, 2011, 00:00

  • PCN112 COMPARISON OF CHARACTERISTICS OF COLORECTAL CANCER PATIENTS ADMITTED EMERGENTLY, URGENTLY OR ELECTIVELY IN WEST VIRGINIA HOSPITALS BETWEEN 2003-2007

    May 1, 2011, 00:00

  • EV3 A COMPARATIVE EFFECTIVENESS INDEX TO INFORM CLINICAL DECISIONS

    May 1, 2011, 00:00

  • PHP63 WHAT INFLUENCES PHARMACEUTICAL REIMBURSEMENT DECISIONS? A SYSTEMATIC REVIEW OF FACTORS REPORTED TO INFLUENCE DECISIONS IN OECD COUNTRIES

    May 1, 2011, 00:00

  • PND37 INVESTIGATION OF THE PSYCHOMETRIC PROPERTIES OF THE SHORT PARKINSON'S EVALUATION SCALE/SCALES FOR OUTCOMES IN PARKINSON'S DISEASE (SPES/SCOPA)

    May 1, 2011, 00:00

  • PUK22 LEVELING THE PLAYING FIELD- A CASE STUDY ON TECHNICAL PRECISION IN COMPARATIVE EFFECTIVENESS RESEARCH FOR CLINICALLY LOCALIZED PROSTATE CANCER (PC)

    May 1, 2011, 00:00

  • PHP105 HOW ARE COVERAGE DECISIONS MADE IN PUBLICLY FUNDED HEALTH CARE PROGRAMS IN LOW- AND MIDDLE-INCOME COUNTRIES?

    May 1, 2011, 00:00

  • PCN93 ATTACHMENT STYLE AND HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH PROSTATE CANCER

    May 1, 2011, 00:00

  • DM1 IMPACT OF A PHARMACY REFILL MANAGEMENT SYSTEM ON OUTCOMES IN END STAGE RENAL DISEASE (ESRD) PATIENTS

    May 1, 2011, 00:00

  • PSY57 DOES CLINICAL DIAGNOSIS OF OBESITY INCREASE THE LIKELIHOOD OF RECEIVING OBESITY RELATED COUNSELING? A 2005-2008 NAMCS-NHAMCS ANALYSIS

    May 1, 2011, 00:00

  • PIH43 METHODOLOGY TO IDENTIFY IN-VITRO FERTILIZATION PATIENTS USING A NATIONAL MANAGED CARE DATABASE

    May 1, 2011, 00:00

  • PDB73 A CLAIMS-BASED EMPIRIC APPROACH TO ASSESSING MEDICATION POSSESSION FOR PATIENTS INITIATING THERAPY WITH INSULINS

    May 1, 2011, 00:00

  • PDB47 NATIONAL IMPACT OF HEALTH CARE ACCESS ON HEALTH-RELATED QUALITY OF LIFE OF PATIENTS WITH DIABETES IN THE UNITED STATES

    May 1, 2011, 00:00

  • Copyright/Subscription

    Mar 1, 2011, 00:00

  • Imputing QALYs from Single Time Point Health State Descriptions on the EQ-5D and the SF-6D- A Comparison of Methods for Hepatitis A Patients

    Mar 1, 2011, 00:00

  • Improvements in Participation in Usual Daily Activities in Patients with Rheumatoid Arthritis Treated with Abatacept

    Mar 1, 2011, 00:00

  • Development of a Conceptual Framework and Calibrated Item Banks to Measure Patient-Reported Dyspnea Severity and Related Functional Limitations

    Mar 1, 2011, 00:00

  • Editorial Board

    Mar 1, 2011, 00:00

  • Predicting EQ-5D Values Using the SGRQ

    Mar 1, 2011, 00:00

  • EQ-5D as a Quality of Life Measure in People with Dementia and Their Carers- Evidence and Key Issues

    Mar 1, 2011, 00:00

  • Cost-Effective Psychotherapy for Personality Disorders in The Netherlands- The Value of Further Research and Active Implementation

    Mar 1, 2011, 00:00

  • Cost-Effectiveness of Transdermal Nitroglycerin Use for Preterm Labor

    Mar 1, 2011, 00:00

  • Treatment with Inhaled Mometasone Furoate Reduces Short-Acting β2 Agonist Claims and Increases Adherence Compared to Fluticasone Propionate in Asthma Patients

    Mar 1, 2011, 00:00

  • Trajectory Classes of Decline in Health-Related Quality of Life in Parkinson's Disease- A Pilot Study

    Mar 1, 2011, 00:00

  • Model Averaging in the Presence of Structural Uncertainty about Treatment Effects- Influence on Treatment Decision and Expected Value of Information

    Mar 1, 2011, 00:00

  • Estimation of Quality-Adjusted Life Expectancy in Patients Under Prolonged Mechanical Ventilation

    Mar 1, 2011, 00:00

  • Cost-Effectiveness of White Blood Cell Growth Factor Use among a Large Nationwide Cohort of Elderly Non-Hodgkin's Lymphoma Patients Treated with Chemotherapy

    Mar 1, 2011, 00:00

  • An Economic Evaluation of Short-Acting Opioids for Treatment of Breakthrough Pain in Patients with Cancer

    Mar 1, 2011, 00:00

  • The Time-Dependent Bias and its Effect on Extra Length of Stay due to Nosocomial Infection

    Mar 1, 2011, 00:00

  • Instructions for Authors

    Mar 1, 2011, 00:00

  • Health Dynamics- Implications for Efficiency and Equity in Priority Setting

    Mar 1, 2011, 00:00

  • Cost-Utility of Laparoscopic Nissen Fundoplication versus Proton Pump Inhibitors for Chronic and Controlled Gastroesophageal Reflux Disease- A 3-Year Prospective Randomized Controlled Trial and Economic Evaluation

    Mar 1, 2011, 00:00

  • Internet-Based Follow-Up Questionnaire for Measuring Patient-Reported Outcome after Total Hip Replacement Surgery—Reliability and Response Rate

    Mar 1, 2011, 00:00

  • How Valuable are Multiple Treatment Comparison Methods in Evidence-Based Health-Care Evaluation?

    Mar 1, 2011, 00:00

  • Health Care Use and Primary Prophylaxis with Colony-Stimulating Factors

    Mar 1, 2011, 00:00

  • Brief, Valid Measures of Dyspnea and Related Functional Limitations in Chronic Obstructive Pulmonary Disease (COPD)

    Mar 1, 2011, 00:00

  • Health-Related Quality of Life after Total Knee Replacement or Unicompartmental Knee Arthroplasty in an Urban Asian Population

    Mar 1, 2011, 00:00

  • Cost-Effectiveness of Sacral Neuromodulation Compared to Botulinum Neurotoxin A or Continued Medical Management in Refractory Overactive Bladder

    Mar 1, 2011, 00:00

  • Table of Contents

    Mar 1, 2011, 00:00

  • Cost-effectiveness analysis of LHRH agonists in the treatment of metastatic prostate cancer in Italy

    Jan 1, 2011, 00:00

  • Cost-effectiveness of infliximab for the treatment of active and progressive psoriatic arthritis

    Jan 1, 2011, 00:00

  • Instructions for Authors

    Jan 1, 2011, 00:00

  • Metric properties of the MacDQoL, individualized macular-disease-specific quality of life instrument, and newly identified subscales in French, German, Italian, and American populations

    Jan 1, 2011, 00:00

  • The CHD challenge- Comparing four cost-effectiveness models

    Jan 1, 2011, 00:00

  • Valuing pharmacogenetic testing services- A comparison of patients' and health care professionals' preferences

    Jan 1, 2011, 00:00

  • Can we account for selection bias? A comparison between bare metal and drug-eluting stents

    Jan 1, 2011, 00:00

  • Reconsidering the value of rehabilitation for patients with cerebrovascular disease in Japanese acute health care hospitals

    Jan 1, 2011, 00:00

  • The economic burden of Medicare-eligible patients by multiple sclerosis type

    Jan 1, 2011, 00:00

  • Uncertainty analysis is inherently Bayesian—Reply to letter to the editor by John Stevens

    Jan 1, 2011, 00:00

  • The use of instrumental variables- An alternative to traditional modeling?

    Jan 1, 2011, 00:00

  • Analysis of EQ-5D scores from two phase 3 clinical trials of romiplostim in the treatment of immune thrombocytopenia (ITP)

    Jan 1, 2011, 00:00

  • Utility values in National Institute for Health and Clinical Excellence (NICE) Technology Appraisals

    Jan 1, 2011, 00:00

  • Using HAQ-DI to estimate HUI-3 and EQ-5D utility values for patients with rheumatoid arthritis in Spain

    Jan 1, 2011, 00:00

  • Table of contents

    Jan 1, 2011, 00:00

  • ISPOR code of ethics

    Jan 1, 2011, 00:00

  • Impact of ACE inhibitors on mortality and morbidity in patients with AMI- Does tissue selectivity matter?

    Jan 1, 2011, 00:00

  • Effect of subcutaneous methylnaltrexone on patient-reported constipation symptoms

    Jan 1, 2011, 00:00

  • Preventable hospital admissions related to medication (HARM)- Cost analysis of the HARM study

    Jan 1, 2011, 00:00

  • Incremental cost-effectiveness of various monthly doses of vardenafil

    Jan 1, 2011, 00:00

  • Valuing health across the lifespan- Health state preferences for seasonal influenza illnesses in patients of different ages

    Jan 1, 2011, 00:00

  • Screenee perception and health-related quality of life in colorectal cancer screening- A review

    Jan 1, 2011, 00:00

  • Cost-effectiveness of bivalirudin versus heparin plus glycoprotein IIb/IIIa inhibitor in the treatment of non–ST-segment elevation acute coronary syndromes

    Jan 1, 2011, 00:00

  • Uncertainty analysis is inherently Bayesian

    Jan 1, 2011, 00:00

  • Copyright/Subscription

    Jan 1, 2011, 00:00

  • Exact method for computing absolute percent change in a dichotomous outcome from meta-analytic effect size- Improving impact and cost-outcome estimates

    Jan 1, 2011, 00:00

  • Is the Health Utilities Index 3 valid for patients with ankylosing spondylitis?

    Jan 1, 2011, 00:00

  • Lung cancer treatment costs, including patient responsibility, by disease stage and treatment modality, 1992 to 2003

    Jan 1, 2011, 00:00

  • The value of budget impact analyses in evaluating targeted therapies—The case of RSV prophylaxis for preterm infants

    Jan 1, 2011, 00:00

  • The cost-utility analysis of adult male circumcision for prevention of heterosexual acquisition of HIV in men in sub-Saharan Africa- a probabilistic decision model

    Jan 1, 2011, 00:00

  • The Value of Correcting Values- Influence and Importance of Correcting TTO Scores for Time Preference

    Dec 1, 2010, 00:00

  • Methods for the Collection of Resource Use Data within Clinical Trials- A Systematic Review of Studies Funded by the UK Health Technology Assessment Program

    Dec 1, 2010, 00:00

  • How Is Evidence on Test Performance Synthesized for Economic Decision Models of Diagnostic Tests? A Systematic Appraisal of Health Technology Assessments in the UK Since 1997

    Dec 1, 2010, 00:00

  • Data Generalizability, Data Transferability, and the Political Economy of Pharmacoeconomic Guidelines

    Dec 1, 2010, 00:00

  • Recent Trends and Geographic Patterns of the Burden of Disease Attributable to Smoking

    Dec 1, 2010, 00:00

  • Development of the EXAcerbations of Chronic Obstructive Pulmonary Disease Tool (EXACT)- A Patient-Reported Outcome (PRO) Measure

    Dec 1, 2010, 00:00

  • Mixed Treatment Comparison Meta-Analysis Evaluating the Relative Efficacy of Nucleos(t)ides for Treatment of Nucleos(t)ide-Naive Patients with Chronic Hepatitis B

    Dec 1, 2010, 00:00

  • Network Meta-Analysis with Competing Risk Outcomes

    Dec 1, 2010, 00:00

  • International Development of the Patient-Reported Outcome Indices for Multiple Sclerosis (PRIMUS)

    Dec 1, 2010, 00:00

  • Cost-Effectiveness of Specialized Multidisciplinary Heart Failure Clinics in Ontario, Canada

    Dec 1, 2010, 00:00

  • Cost–Utility Analysis of Tenofovir Disoproxil Fumarate in the Treatment of Chronic Hepatitis B

    Dec 1, 2010, 00:00

  • The Role of Observational Investigations in Comparative Effectiveness Research

    Dec 1, 2010, 00:00

  • Estimating the Effect of Medication Adherence on Health Outcomes among Patients with Type 2 Diabetes—An Application of Marginal Structural Models

    Dec 1, 2010, 00:00

  • Discrete Choice Modeling for the Quantification of Health States- The Case of the EQ-5D

    Dec 1, 2010, 00:00

  • Expanded HIV Screening in the United States- What Will It Cost Government Discretionary and Entitlement Programs? A Budget Impact Analysis

    Dec 1, 2010, 00:00

  • Cost-Effectiveness of Maraviroc for Antiretroviral Treatment-Experienced HIV-infected Individuals in Mexico

    Dec 1, 2010, 00:00

  • Functional Impairment and Disability across Mood States in Bipolar Disorder

    Dec 1, 2010, 00:00

  • Discrete Event Simulation- The Preferred Technique for Health Economic Evaluations?

    Dec 1, 2010, 00:00

  • Use of a Disease-Specific Instrument in Economic Evaluations- Mapping WOMAC onto the EQ-5D Utility Index

    Dec 1, 2010, 00:00

  • Is Longer Waiting Time for Total Knee Replacement Associated with Health Outcomes and Medication Costs? Randomized Clinical Trial

    Dec 1, 2010, 00:00

  • Willingness to Pay for a Quality-Adjusted Life-Year- The Individual Perspective

    Dec 1, 2010, 00:00

  • Historical Lifetimes of Drugs in England- Application to Value of Information and Cost-Effectiveness Analyses

    Dec 1, 2010, 00:00

  • Predicting Time Trade-Off Health State Valuations of Adolescents in Four Pacific Countries Using the Assessment of Quality-of-Life (AQoL-6D) Instrument

    Dec 1, 2010, 00:00

  • What Do International Pharmacoeconomic Guidelines Say about Economic Data Transferability?

    Dec 1, 2010, 00:00

  • Erratum

    Dec 1, 2010, 00:00

  • Economic Evaluations Alongside Effectiveness Trials

    Dec 1, 2010, 00:00

  • Reviewer Acknowledgment

    Dec 1, 2010, 00:00

  • PSY42 COST-EFFECTIVENESS ANALYSIS OF BIOLOGICS IN THE TREATMENT OF MODERATE TO SEVERE PSORIASIS IN THE PUBLIC HEALTH CARE SYSTEM OF BRAZIL

    Nov 1, 2010, 00:00
  • «
  • 121
  • 122
  • 123
  • 124
  • 125
  • 126
  • 127
  • 128
  • 129 (current)
  • 130
  • »